Development of TRNT radiopharmaceuticals targeting Hsp90 KU Leuven
Pancreatic cancer and advanced glioma are life threating diseases, currently untreatable and with high chance of recurrence or dissemination. There is a clear need for new treatment strategies. In this respect, targeted radionuclide therapy can offer solace. Heat shock protein 90 (Hsp90) has been widely investigated as a target in different cancers as it display characteristics which only occur in malignant cells (higher expression, increased ...